TFRC and neoplasm: For example, the transferrin receptor has been targeted by transferrin–drug conjugates and peptide-guided nanoparticles to ferry chemotherapeutics across the BBB and into tumor cells (Johnsen et al., 2019; Thomsen et al., 2022).